For years, we have tried to align our market access and R&D departments in order to maximize launch options without adding significantly delays and development costs.
It’s time to regroup and determine what the best path forward might be during 2018 and beyond. Should we be aiming for early, phased access? Should we continue to emphasize the focus of involving access departments, being HEOR, strategic pricing/access and Medical Affairs early in the lifecycle to maximize launch? There are hundreds of different variables to consider.
In our latest webinar, our industry experts will discuss their views on, what promises to be, a very interesting debate.